A Phase III study of patients with Breast Cancer receiving anthracycline-cyclophosphamide (AC) chemotherapy revealed that NEPA (netupitant and palonosetron), from...
Palonosetron Accord is indicated in adults for: • the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, • the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Palonosetron Accord is indicated in paediatric patients 1 month of age and older for. • the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.